Analyst Reco. Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
397.5 ^USD	-0.06%		+0.81%	-2.31%

Apr. 26	Vertex Pharmaceuticals Gets European Commission Approval for Cystic Fibrosis Treatment for Infants	MT
Apr. 26	Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $497 From $515	Apr. 25	MT
UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating	Apr. 17	MT
Guggenheim Adjusts Vertex Pharmaceuticals' Price Target to $450 From $445	Apr. 17	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
HC Wainwright Raises Vertex Pharmaceuticals' Price Target to $462 From $457, Maintains Buy Rating	Apr. 11	MT
Wedbush Downgrades Alpine Immune Sciences to Neutral From Outperform, Raises Price Target to $65 From $47, Expects Vertex Deal to Close	Apr. 11	MT
Evercore ISI Upgrades Vertex Pharmaceuticals to Outperform From In Line	Apr. 11	MT
RBC Downgrades Alpine Immune Sciences to Sector Perform From Outperform, Removes Speculative Risk, Lifts Price Target to $65 From $41 Amid Vertex Deal	Apr. 11	MT
RBC Trims Price Target on Vertex Pharmaceuticals to $417 From $420, Keeps Sector Perform Rating	Feb. 22	MT
Wolfe Research Initiates Vertex Pharmaceuticals With Outperform Rating, $515 Price Target	Feb. 15	MT
Fed officials fail to convince investors, who are focused on earnings	Feb. 07
ANALYST RECOMMENDATIONS : Caterpillar, Eli Lilly, Intel, Meta, T-Mobile...	Feb. 07
Stifel Adjusts Vertex Pharmaceuticals' Price Target to $430 From $373, Keeps Hold Rating	Feb. 06	MT
Leerink Partners Adjusts Vertex Pharmaceuticals' Price Target to $511 From $485, Keeps Outperform Rating	Feb. 06	MT
Goldman Sachs Adjusts Vertex Pharmaceuticals' Price Target to $578 From $559, Keeps Buy Rating	Feb. 06	MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $540 From $500, Maintains Overweight Rating	Feb. 06	MT
UBS Adjusts Price Target on Vertex Pharmaceuticals to $498 From $513, Maintains Buy Rating	Feb. 06	MT
Evercore ISI Downgrades Vertex Pharmaceuticals to In Line From Outperform, Adjusts Price Target to $438 From $436	Feb. 06	MT
JPMorgan Adjusts Price Target on Vertex Pharmaceuticals to $450 From $438, Keeps Overweight Rating	Feb. 06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Vertex Pharmaceuticals Incorporated : Vertex and Crispr to market $2.2 million treatment for sickle cell disease

December 11, 2023 at 05:47 am EST